Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OsteoTorrent
- Development stage
- Unknown
- Lead developer
- SeaSpine
- Administration
- Topical
01
Overview
OsteoTorrent is a demineralized bone matrix (DBM) putty developed by SeaSpine Holdings Corporation (now part of Orthofix). It is a biologic bone graft substitute composed of a combination of demineralized bone matrix and demineralized porous cancellous bone (access bone matrix). Designed for use in spinal fusion and other orthopedic procedures, the product is packaged and sterilized in a dry state, allowing surgeons to reconstitute it with saline, blood, or bone marrow aspirate. This formulation is intended to maximize osteoinductive potential and provide a long shelf-life. It builds upon the technology used in SeaSpine's Evo3 and OsteoSurge 300 product lines.
- Brand names
- OsteoTorrent
Beyond the preview
Go deeper on OsteoTorrent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OsteoTorrent.